Where evaluated, rates of outcomes were generally similar between countries.
Many of the above studies evaluated rates of IPF by age and sex.
We further evaluated rates of warfarin use among stroke risk and bleeding risk category combinations and compared overall usage rates with earlier studies.
To determine the mechanism by which ML240 and ML241 inhibited p97 ATPase, we evaluated rates of ATP hydrolysis at different concentrations of ATP.
Only one study evaluated rates of spontaneous abortion following use of 2,4-D during the pregnancy period (Arbuckle et al., 1999; Arbuckle et al., 2001).
For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score.
When we evaluated rates of GvHD, we found higher fractions of historical patients had acute and chronic GvHD for patients receiving matched related or matched unrelated transplants, further suggesting treatment effect.
We have previously used combined patient-level VHA and Medicare databases to develop risk prediction models for total (15) and minor and major amputations (11) and evaluated rates of initial versus repeat amputations (16).
For the survivor group we evaluated rates of delivery by diagnosis, categorizing survivors into broad groups including the diagnoses with at least 100 women (brain, breast, Hodgkin lymphoma, non-hodgkin lymphoma [NHL], melanoma, thyroid and other malignancies).
Continuous outcome measures with several follow-up assessments would allow us to evaluate rate of recovery.
